期刊
ONCOTARGET
卷 8, 期 5, 页码 8083-8094出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.14097
关键词
uncoupling protein 2 (UCP2); non-small cell lung cancer (NSCLC); chemotherapeutic resistance; hypoxia; PPAR-gamma
资金
- National Natural Science Foundation of China [81472631, 11374237, 31200429]
- Natural Science Basic Research Plan in Shaanxi Province of China [2015JZ024]
- China Postdoctoral Science Foundation [2014M560759]
Hypoxic microenvironment is critically involved in the response of non-small cell lung cancer (NSCLC) to chemotherapy, the mechanisms of which remain largely unknown. Here, we found that NSCLC patients exhibited increased chemotherapeutic resistance when complicated by chronic obstructive pulmonary disease (COPD), a critical cause of chronic hypoxemia. The downregulation of uncoupling protein 2 (UCP2), which is attributed to hypoxia-inducible factor 1 (HIF-1)-mediated suppression of the transcriptional factor peroxisome proliferator-activated receptor. (PPAR.), was involved in NSCLC chemoresistance, and predicted a poor survival rate of patients receiving routine chemotherapy. UCP2 suppression induced reactive oxygen species production and upregulation of the ABC transporter protein ABCG2, which leads to chemoresistance by promoting drug efflux. UCP2 downregulation also altered metabolic rates as shown by elevated glucose uptake and reduced oxygen consumption. These data suggest that UCP2 is a key mediator of hypoxia-triggered chemoresistance of NSCLCs, which can be potentially targeted in clinical treatment of chemo-refractory NSCLCs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据